Physician profile
Robert Warner
NPI 1609801315
$2,362.20
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $578 · 2020: $112 · 2021: $225 · 2022: $837 · 2023: $197 · 2024: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $525 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $524.90 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $550.00 | 2022 | |
| Lilly USA, LLC | $358.42 | 2019-2024 | Verzenio, Retevmo, Jaypirca |
| E.R. Squibb & Sons, L.L.C. | $270.15 | 2019-2024 | Opdualag, Opdivo, Krazati |
| Amgen INC. | $156.62 | 2019-2023 | Kyprolis, Blincyto, Lumakras |
| Incyte Corporation | $141.35 | 2021-2022 | |
| Sobi, INC | $117.99 | 2024 | |
| Comsort, INC | $100.00 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $86.93 | 2020-2022 | |
| Genentech USA, INC. | $64.95 | 2019-2024 | Polivy, Lunsumio, Columvi |
| Merck Sharp & Dohme LLC | $58.74 | 2019-2024 | Keytruda |
| Servier Pharmaceuticals LLC | $36.35 | 2023-2024 | |
| Astrazeneca Pharmaceuticals Lp | $34.40 | 2019 | |
| Rigel Pharmaceuticals, INC. | $33.34 | 2019 | |
| Genzyme Corporation | $33.21 | 2019-2020 | |
| Pfizer INC. | $32.41 | 2019-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $27.72 | 2019 | |
| Eisai INC. | $23.98 | 2024 | |
| Celgene Corporation | $23.42 | 2019 | |
| Janssen Biotech, INC. | $19.60 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.55 | 2019 | |
| Morphosys, US INC. | $18.35 | 2021 | |
| Tersera Therapeutics LLC | $17.90 | 2019 | |
| Aveo Pharmaceuticals, INC. | $17.61 | 2023 | Fotivda |
| Abbvie INC. | $17.37 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.52 | 2019 | |
| Sun Pharmaceutical Industries INC. | $14.17 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $13.97 | 2019 | |
| Shire North American Group INC | $13.82 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.44 | 2020 | |
| Clovis Oncology, INC. | $11.92 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Heron Therapeutics, INC. | $10.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Warner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.